Aflac's Q2 Miss Masked a Better Story: Japan Momentum, Buybacks, and the 14.4x Bet

A one-cent EPS miss did not fully capture the quarter

Aflac's one-cent EPS miss dominated the headline, but the broader quarter was less broken than that suggested. Adjusted EPS declined 1.7%, revenue slipped 1.0%, and revenue still came in above consensus. With the stock trading at about 14.35x trailing earnings, the more useful question is whether investors should focus on a penny miss or on a business that remained broadly stable.

The bull case is straightforward: Aflac still produced a quarter consistent with solid operational performance and revenue growth above Wall Street expectations. The bear case also has merit-adjusted earnings decreased 7.7% year over year, which shows the profit stream was not smooth. Even so, at roughly 14.4x trailing earnings, Aflac does not look priced like a broken insurer.

Miraito gave Japan a new sales lever, but follow-through still has to be proven

The more constructive part of the quarter was where new demand showed up. Aflac's Miraito cancer insurance product helped drive a 53% increase in cancer policy sales and contributed to a 23.2% year-over-year sales rise in Japan. That matters because fresh product demand can restart buyer interest, support agent enthusiasm, and build a larger base of future premiums.

The debate, though, is real. Aflac Japan still reported a 5.6% quarter-over-quarter sales decline to ¥19.6 billion, even though first-half sales were up 7%. Skeptics will argue that Miraito may produce a short-lived launch boost. The more constructive read is that management and analysts pointed to the product's flexible design and new service features as factors that could help momentum extend beyond the typical launch cycle.

U.S. operations look steady, but the quarter still had profit pressure

The cleaner support for the story is persistence. Japan's premium persistency remained solid at 92.7%, and analysts also highlighted strategic underwriting and expense management helping preserve U.S. margins. That does not erase the earnings decline, but it does suggest the business is still holding policyholders and protecting margins better than the headline miss implies.

What investors need to see next is fairly simple: - Japan sales firm up after the Miraito launch effect fades. - U.S. underwriting and expense discipline continue to support margins. - Persistency remains steady instead of slipping as management chases volume.

The earnings decline was real, and investment returns were the clearest pressure point

This quarter still stings because the earnings decline was real, not an accounting artifact. Adjusted earnings fell 7.7%, and one of the clearest pressure points was variable investment income $0.11 per diluted share below long-term return expectations. That matters because investment shortfalls hit the profit stream directly.

Currency and accounting items complicated the read

The underlying business still looked reasonably resilient. The annualized adjusted return on equity excluding foreign currency remeasurement was 16.6%, which suggests the core spread remained solid even with Japan's currency effects in the reported numbers.

The quarter was not a perfectly clean operating print, however. Aflac said a $26 million expense contingency was released, benefiting results by $0.04 per share, while reserve remeasurement gains totaled $46 million, or $0.01 per diluted share below plan. In other words, part of the quarter received a small offset, which makes the underlying profit pressure harder to dismiss.

That leaves the investment return gap as the most straightforward operating concern. Adjusted book value per share excluding foreign currency remeasurement decreased 4.1%, reinforcing the idea that the quarter was not entirely smooth. It does not prove a broken model, but it does argue against treating the quarter as a clean reset.

Aflac still looks more like a hold-or-add-on than a turnaround trade

The case for owning Aflac here is not that the quarter was strong. It is that the company is still generating cash and returning capital while investors wait for the next proof point. Aflac recently returned $1.3 billion to shareholders through repurchases and dividends, and management referenced its 43 consecutive years of dividend increases.

That backdrop matters. If the business can keep returning capital while Japan builds on Miraito and U.S. margins remain disciplined, the stock can hold up even if the market stays cautious. If investment returns and sales momentum worsen, however, the multiple can compress again.

What to watch next

Watch these items on or near the August 7, 2026 webcast and at the November 4, 2026 third-quarter release: - Whether Japan sales stabilize after the Miraito launch. - Whether U.S. margins remain protected rather than traded away for volume. - Whether persistency holds steady. - Whether investment returns move back toward long-term expectations.